Teva Pharmaceuticals is the 'stalking horse bidder' to kick off the auction process for BioXcel Therapeutics' AI-derived ...

Lisraya carries a boxed warning typical of JAK inhibitors, but otherwise has a broad label that allows use in all adults with ...

Shares of Germany-based BioNTech were down as much as 8% Friday after announcing a Phase 2 trial of autogene cevumeran would ...

With the approval, Eli Lilly’s Mounjaro becomes the first dual GIP/GLP-1 receptor agonist indicated to lower the risk of ...

Even without specific Phase 3 data yet revealed, analysts see AstraZeneca and Amgen’s Tezspire as a potential threat for ...

Manufacturers are being pushed beyond mAb‑era platforms into a new design model built around molecular engineering, complex ...

AstraZeneca and Ionis Pharmaceuticals’ data drop divulging more details from its highly watched Phase 3 transthyretin ...

AstraZeneca and Amgen co-develop and co-commercialize Tezspire under an April 2012 agreement. The partners are now planning ...

Current leaders Eli Lilly and Novo Nordisk have cornered the early market for weight loss therapeutics, but several other ...

The FDA granted the approval of Revolution Medicines' daraxonrasib, now to be known as Rasonque, in pancreatic adenocarcinoma ...

Thanks in part to the revolution cell therapy brought to treating blood cancers, the modality is now showing promise in some ...

Limited opportunities and burnout are just two reasons biopharma professionals stop looking for work, with some pivoting away ...